BL
EWTX icon

BFSG LLC’s Edgewise Therapeutics EWTX Stock Holding History

BFSG LLC’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06K Hold
100
– – ﹤0.01% 644
2026
Q1 		$3.15K Hold
100
– – ﹤0.01% 649
2025
Q4 		$2.48K Hold
100
– – ﹤0.01% 638
2025
Q3 		$1.62K Hold
100
– – ﹤0.01% 647
2025
Q2 		$1.31K Hold
100
– – ﹤0.01% 625
2025
Q1 		$2.2K Sell
100
-200
-67% -$5.25K ﹤0.01% 601
2024
Q4 		$8.01K Sell
300
-300
-50% -$9.55K ﹤0.01% 520
2024
Q3 		$16K Hold
600
– – ﹤0.01% 459
2024
Q2 		$10.8K Buy
+600
New +$10.5K ﹤0.01% 472

Other funds holding EWTX

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CCMG
Connecticut Capital Management Group Milford, Connecticut $124M AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

BFSG LLC's EWTX Position: Q2 2026 in Review

BFSG LLC held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 100 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #644.

BFSG LLC first reported a position in EWTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $16K in Q3 2024. 17 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • BFSG LLC held 100 shares of Edgewise Therapeutics worth $4.06K as of Q2 2026.
  • BFSG LLC left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #644 holding.
  • BFSG LLC first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • BFSG LLC's Edgewise Therapeutics position peaked at $16K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.